Mark Sullivan Buys Shares of Definium Therapeutics
Definium's Chief Legal Officer, Mark Sullivan, acquired 62,500 shares of the company.
Key Points
- Mark Sullivan, Definium Therapeutics' Chief Legal Officer, bought 62,500 shares on June 22, 2026.
- Definium Therapeutics, Inc. trades on NasdaqGS, with a market cap of approximately $2.67 billion and a 52-week high of $26.25.
- Analysts have a strong buy consensus with a mean price target of $39.87, reflecting positive sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mark Sullivan, the Chief Legal Officer at Definium Therapeutics, Inc. (NasdaqGS: DFTX), made a significant move by purchasing 62,500 shares of the company on June 22, 2026. This insider activity highlights confidence from the company’s leadership as shares traded near $24.48 on Monday.
Insider Buying and Selling at Definium Therapeutics, Inc.
Several insiders at Definium Therapeutics, including Chief Medical Officer Daniel Karlin and Chief Financial Officer Brandi Roberts, also bought shares on June 22, 2026. CEO Robert Barrow made the largest purchase, acquiring 375,000 shares. These transactions were not planned under Rule 10b5-1 plans, indicating spontaneous confidence in the company.
Other Institutional Activity in Definium Therapeutics
Several institutional investors have shown interest in Definium Therapeutics. BlackRock, Inc. opened a new position with 8,480,230 shares valued at about $160.28 million. Driehaus Capital Management LLC reduced its stake by 625,313 shares, now holding 5,911,889 shares worth around $111.73 million, marking a 9.6% decrease. Avoro Capital Advisors LLC also opened a new position with 5,000,000 shares valued at approximately $94.5 million.
Definium Therapeutics, Inc. Stock Down 10.5%
Shares of Definium Therapeutics traded near $24.48 on Monday. The company, with a market cap of about $2.67 billion, operates in the biotechnology sector. It has a 52-week high of $26.25 and a low of $6.35, indicating significant volatility. The stock's forward P/E ratio isn't meaningful due to negative earnings, but it has a high beta of 2.378, suggesting greater volatility compared to the market.
$DFTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts remain optimistic about Definium Therapeutics' future. On June 16, 2026, Canaccord Genuity maintained a buy rating with a target price of $38. Piper Sandler has also maintained a buy rating with a target of $48 as of May 8, 2026. Overall, the consensus among analysts is a strong buy, with a mean price target of $39.87 based on 15 opinions.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, specializing in developing treatments for brain health disorders. Its main products include DT120, in phase 3 trials for anxiety and depressive disorders, and DT402, in phase 2a trials for autism spectrum disorder. Led by CEO Robert Barrow, Definium employs 105 people, focusing on innovative therapies to address unmet medical needs.
Bottom Line
Mark Sullivan's purchase of shares in Definium Therapeutics is a clear signal of insider confidence. The company's volatile stock has drawn interest from institutional investors and analysts alike, with a strong buy consensus. As always, remember that insider transactions and 13F filings reflect past actions and may not indicate current positions or future performance.
Get Definium Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DFTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.